Adagene Inc - ESG Rating & Company Profile powered by AI
The analysis of Adagene Inc incorporates data from across the web as well as from available disclosures by Adagene Inc. This SDG score for Adagene Inc indicates its reporting of the United Nations SDGs. The page is a zero-cost ESG assessment for Adagene Inc.
Adagene Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.6; made up of an environmental score of 0.0, social score of 3.2 and governance score of 1.6.
1.6
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1682 | Viracta Therapeutics Inc | 1.7 | Low |
| 1682 | Werewolf Therapeutics Inc | 1.7 | Low |
| 1715 | Adagene Inc | 1.6 | Low |
| 1715 | CareDx Inc | 1.6 | Low |
| 1715 | Catalyst Biosciences Inc | 1.6 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Adagene Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Adagene Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Adagene Inc report the average age of the workforce?
Sign up for free to unlockDoes Adagene Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Adagene Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Adagene Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Adagene Inc offer flexible work?
Sign up for free to unlockDoes Adagene Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Adagene Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Adagene Inc conduct supply chain audits?
Sign up for free to unlockDoes Adagene Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Adagene Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Adagene Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Adagene Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Adagene Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Adagene Inc disclose water use targets?
Sign up for free to unlockDoes Adagene Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Adagene Inc have a product recall in the last two years?
Sign up for free to unlockDoes Adagene Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Adagene Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Adagene Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Adagene Inc disclose parental leave metrics?
Sign up for free to unlockDoes Adagene Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Adagene Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Adagene Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Adagene Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Adagene Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Adagene Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Adagene Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Adagene Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Adagene Inc disclose its waste policy?
Sign up for free to unlockDoes Adagene Inc report according to TCFD requirements?
Sign up for free to unlockDoes Adagene Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Adagene Inc disclose energy use targets?
Sign up for free to unlockDoes Adagene Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Adagene Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Adagene Inc
These potential risks are based on the size, segment and geographies of the company.
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.